PHILADELPHIA, Sept. 5, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its needle-free Symphony® CGM System as a non-invasive, wireless, continuous glucose monitoring system, announced that the independent members of the Board of Directors and Mr. Robert F. Doman, the Executive Chairman and Interim Chief Executive Officer, today sent a letter to its shareholder, Platinum-Montaur Life Sciences, LLC, in response to an August 30, 2013 public communication made by Platinum-Montaur and its affiliated funds. In addition, Echo has communicated with Platinum-Montaur to discuss the matters raised in the August 30, 2013 communication. The Company and Platinum-Montaur have scheduled a meeting for next week.
As Echo has previously announced, it continues to consider and seek to enter into collaborations or licenses regarding the future development and distribution of its products and remains willing to enter into discussions regarding potential collaborations or licenses.
About Echo Therapeutics
Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system for use initially in the critical care setting. Significant opportunity also exists for Symphony to be used in the hospital beyond the critical care setting, as well as in patients with diabetes in the outpatient setting. Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectation
|SOURCE Echo Therapeutics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved